Advanced Search

Amendment Of The Cabinet Of Ministers On 19 July 2005, The Provisions Of The "rules On No 528 National Agency" Infektoloģij Center "public Service Price List"

Original Language Title: Grozījums Ministru kabineta 2005.gada 19.jūlija noteikumos Nr.528 "Noteikumi par valsts aģentūras "Latvijas infektoloģijas centrs" publisko pakalpojumu cenrādi"

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now for only USD$40 per month.
Cabinet of Ministers Regulations No. 402 Riga, 5 May 2009 (pr. No 29 51) amendment to the Cabinet on 19 July 2005, the provisions of the "rules on no 528 national agency" infektoloģij Center "public service price list" Issued in accordance with the law on budget and financial management of the ninth paragraph of article 5 to make a Cabinet of 19 July 2005, regulations No 528 "rules for State agencies Kuma" infektoloģij Center "public service price list" (Latvian journal, 2005, 115 No; 2006, 2007 101 no; 88. no; 2008, 114 no). amendments and express attachment as follows: "Cabinet of Ministers on 19 July 2005, regulations No 528 national agency" infektoloģij Center "public service price list no PO box
The type of service the unit price without VAT (Ls) excluding VAT (Ls) price with VAT (Ls) (I). the public services on which the associated costs shall not be covered from the State budget of 1.
Vaccination and the preparation of 1.1 imūnbioloģisk.
vaccination against tick encephalitis for 1.1.1.
vaccination against tick encephalitis (adults) 1 vaccination 21.50 0.00 21.50 1.1.2.
vaccination against tick encephalitis (children) 1 vaccination 21.00 0.00 21.00 1.2.
pretērč immune globulin injection of encephalitis vaccination 20.00 0.00 20.00 1.3 1.
vaccination against vaccination of disease 1 crazy 14.00 0.00 14.00 1.4.
vaccination against yellow fever vaccination 18.00 0.00 18.00 1 1.5.
vaccination against hepatitis virus in 1.5.1.
vaccination against viral hepatitis A (growth of guš) 1 vaccination 22.00 0.00 22.00 1.5.2.
vaccination against vīrushep's clouded A (children) (1) vaccination 19.00 0.00 19.00 1.5.3.
vaccination against vīrushep send the B (growth of guš) 1 vaccination 12.00 0.00 12.00 1.5.4.
vaccination against vīrushep send the B (children) 1 vaccination 9.00 0.00 9.00 1.5.5.
vaccination against vīrushep and the men of the cue (A) hepatitis B (combined vaccine in a single dose) 1 vaccination 31.00 0.00 31.00 1.6.
vaccination against chickenpox vaccination 30.00 0.00 30.00 1.7 1.
vaccination against typhoid fever vaccination 12.00 0.00 12.00 1.8 1.
vaccination against diphtheria in the rain, poliom, numbness of cramps 1 vaccination 11.00 0.00 11.00 1.9.
vaccination against manning tree infection 1 vaccination 14.00 0.00 14.00 1.10.
vaccination against pneim infection of 1 vaccination 15.00 0.00 15.00 1.11.
vaccination against influenza is 1.11.1.
vaccination against the flu (adults) 1 vaccination 8.00 0.00 8.00 1.11.2.
vaccination against influenza vaccination (children) 1 7.00 0.00 7.00 1.12.
vaccination against cholera vaccination 23.00 0.00 23.00 1.13 1.
vaccination against epidemic of mumps, measles, rubella vaccination 1 12.00 0.00 12.00 1.14.
international certificate of vaccination or revakc in the nation against the yellow fever certificate 0.60 0.13 0.73 1 1.15.
off-site vaccination 1.15.1.
vaccinations work collective (up to 50 lift when) 1 sail 12.00 0.00 12.00 1.15.2.
vaccinations work collective (from 51 to 100 people) 1 sail 22.00 0.00 22.00 1.15.3.
vaccinations work collective (from 101 to 200 people) 1 sail 32.00 0.00 32.00 1.15.4.
vaccinations work collective (from 201 to 300 people) 1 sail 2 42.00 0.00 42.00.
Dentist Services ** 2.1.
a first investigation and history data collection study 4.24 0.00 4.24 1 2.2.
Repeat investigation after six months 1 study 2.12 0.00 2.12 2.3.
determination of tooth vitality one tooth 1 study 0.72 0.00 0.72 2.4.
tooth higiēnist of 1 consultation consultation 2.38 0.00 2.38 2.5.
written one treatment plan 1 plan 1.86 0.00 1.86 2.6.
x-ray evaluation of assessment 1 1.14 0.00 1.14 2.7.
hygiene instruction and motivation 1 instruction 2.38 0.00 2.38 2.8.
the tooth surface treatment with pretkaries feature 1 procedure 2.59 0.00 2.59 2.9.
the tooth remove fever throughout the soft mouth 1 procedure 3.05 0.00 3.05 2.10.
the old seals into 1 procedure 0.93 0.00 0.93 2.11.
Tartar removal and polishing (one unit of time) 1 procedure 6.73 0.00 6.73 2.12.
tooth kavitāt and karioz of the mass removal, including the temporary closure of the kavitāt 1 procedure 4.45 0.00 4.45 2.13.
tooth kavitāt creation and indirect pulp capping with calcium hydroxide (Ca (OH) 2), including the temporary closure of the kavitāt 1 procedure 6.78 0.00 6.78 2.14.
kavitāt creation, with composite plombējam material, including the lining of insertion, matrix taxation or other AIDS to the use of seals and seal polishing 2.14.1.
incisīv, one surface 1 procedure 8.95 0.00 8.95 2.14.2.
incisīv, two surface 1 procedure 10.35 0.00 10.35 2.14.3.
premolār, one surface 1 procedure 8.95 0.00 8.95 2.14.4.
premolār, two surface 1 procedure 10.61 0.00 10.61 2.14.5.
molar, one surface 1 procedure 8.95 0.00 8.95 2.14.6.
molar, two surface 1 procedure 12.42 0.00 12.42 2.15.
kavitāt creation, with composite plombējam material, including the lining of insertion, matrix taxation or other AIDS to the use of seals and seal polishing 2.15.1.
incisīv, three surface 1 procedure 13.97 0.00 13.97 2.15.2.
incisīv, four surface 19.87 0.00 19.87 2.15.3 procedure 1.
premolār, three surface 1 procedure 23.81 0.00 23.81 2.15.4.
premolār, four surface 1 procedure 28.98 0.00 28.98 2.15.5.
Clinical Crown restoration procedure 1 27.95 0.00 27.95 2.16.
in the teeth of the vital pulpekstirpācij viensakn 1 procedure 8.02 0.00 8.02 2.17.
pulpekstirpācij divsakņ of the teeth in vital 1 procedure 10.35 0.00 10.35 2.18.
pulpekstirpācij trīssakņ of the teeth in vital 1 procedure 14.90 0.00 14.90 2.19.
drug insert 1 procedure starpseanso 1.40 0.00 1.40 2.20.
root canal treatment of tooth 1 procedure viensakn 5.54 0.00 5.54 2.21.
root canal filling of teeth 1 procedure viensakn 4.35 0.00 4.35 2.22.
root canal treatment of tooth divsakņ 1 procedure 6.99 0.00 6.99 2.23.
root canal filling of divsakņ dental procedure 1 7.14 0.00 7.14 2.24.
root canal treatment of tooth trīssakņ (one to two sessions) 1 procedure 11.59 0.00 11.59 2.25.
root canal filling teeth 1 procedure trīssakņ 9.47 0.00 9.47 2.26.
root canal of tooth viensakn pārārstēšan of 1 procedure 9.52 0.00 9.52 2.27.
root canal of tooth pārārstēšan divsakņ 1 procedure 11.07 0.00 11.07 2.28.
root canal of tooth pārārstēšan trīssakņ 1 procedure 13.66 0.00 13.66 2.29.
endodontisk to open the tooth treated through Crown 1 procedure 3.62 0.00 3.62 2.30.
viensakn-tooth extraction wound decoration, 1 procedure 4.86 0.00 4.86 2.31.
daudzsakņ tooth extraction, including wounds finish procedure 1 8.69 0.00 8.69 2.32.
redirected or thin tooth extraction procedure 1 15.78 0.00 15.78 2.33.
mucous diseases local drug treatment procedure 4.81 0.00 4.81 1 2.34.
surface anesthesia procedure 1 1.55 0.00 1.55 2.35.
infiltration anesthesia procedure 1 1.66 0.00 1.66 2.36.
District 1 anesthesia procedure 2.59 0.00 2.59 2.37.
local medication (gel) into gum Pocket 1 procedure 1.50 0.00 1.50 3.
3.1 the service services.
with treatment related services ** 3.1.1.
Insert a single patient in Ward 1 days of 8.00 0.00 8.00 3.1.2.
Insert 1 patient days of boxing 12.00 0.00 12.00 3.1.3.
detoxification of alcohol intoxication and withdrawal to the stationary blending (one day) 1 days-29.00 0.00 29.00 3.1.4.
detoxification of alcohol intoxication and blending of fixed abstinen ces (two nights) for 2 days of 51.00 0.00 51.00 3.2.
medical records copying 3.2.1.
A5 copy with copy machine for A5 page 0.04 0.01 0.05 3.2.2.
A4 copies with copy machine for A4 sheet 0.05 0.01 0.06 3.2.3.
repeating the statement preparation and after issuing a written request within one week 1 document 4.28 0.90 5.18 3.2.4.
repeating the statement preparation and service the next day after receipt of the request 1 document 6.93 1.46 8.39 3.2.5.
extract translation in a foreign language (English, Russian) 1 document 5.78 1.21 6.99 3.2.6.
inability to duplicate issue 1 page document 1.00 0.21 1.21 4.
Methodically consultative work 4.1.
laboratory specialist training (with the exception of the epidemiological surveillance laboratory professionals) 1 academic hour 6.38 1.34 7.72 4.2.
training of laboratory methods 1 participant 6.38 1.34 7.72 4.3.
a thematic workshop on laboratory diagnosis (of each member) 1 member 9.60 2.02 11.62 4.4.
Lecture on diagnosis (from each participant) participant 3.17 0.67 3.84 1 4.5.
training vakcinoloģij infektoloģij Centre of Latvia in the vaccination room (from each participant) participant 12.76 2.68 15.44 1 4.6.
methodically advisory work in the prevention of infectious diseases issues 1 study 12.76 2.68 15.44 II. Public services that are provided to a person without a family doctor or specialist referral outpatient or inpatient investigation and treatment 5.
Health care in outpatient department

5.1. outpatient consultations 5.1.1.
the professor's advice (first inspection) 1 consultation 35.00 0.00 35.00 5.1.2.
the professor's advice (see again) 1 consultation 20.00 0.00 20.00 5.1.3.
Assistant Professor counseling (first inspection) 1 consultation 25.00 0.00 25.00 5.1.4.
Assistant Professor counseling (re view) 1 consultation 15.00 0.00 15.00 5.1.5.
certified infektolog, therapist, Pediatrics, dermatovenerolog, gynecologist, surgeon, neurologist, hepatolog, psychotherapist, otorinolaringolog consulting (first inspection) 1 consultation 20.00 0.00 20.00 5.1.6.
certified infektolog, therapist, Pediatrics, dermatovenerolog, gynecologist, surgeon, nei rolog, hepatolog, psychotherapist, otori NOLA ringolog consultation (see again) 1 consultation 10.00 0.00 10.00 5.1.7.
infektolog consultation tropical disease (at the time) 1 consultation 8.00 0.00 8.00 5.1.8.
infektolog consultation tropical disease (out of time) 1 consultation 10.00 0.00 10.00 5.1.9.
okulist inspection and spectacle out 1 study 3.50 0.00 3.50 5.1.10.
the radiologist consultation 1 study 4.00 0.00 4.00 5.1.11.
gynecologist, preventive inspection specialist 1 study 7.55 0.00 7.55 5.1.12.
ophthalmologist preventive inspection 1 study 7.85 0.00 7.85 5.1.13.
preventive examination 1 otorinolaringolog study 6.30 0.00 6.30 5.1.14.
Occupational medical examination 1 study 6.00 0.00 6.00 5.2.
the injection takes place in 5.2.1.
the skin of the injection 1 injection 0.52 0.00 0.52 5.2.2.
hypodermic injection 1 injection 0.52 0.00 0.52 5.2.3.
injection muscle 1 injection 0.52 0.00 0.52 5.2.4.
injection of vein 1 injection 1.56 0.00 1.56 5.2.5.
sampling of blood from veins 1 injection 1.04 0.00 1.04 5.2.6.
vakutainer 1 injection 0.16 0.00 0.16 6.
Hospital profile patient days (without the diagnostic studies) 1 days-42.00 0.00 42.00 7.
Laboratory studies 7.1.
clinical study in 7.1.1.
investigation of blood, unmodified.
White (adding the camera) 1 study 0.62 0.00 0.62 7.1.1.2.
retikulocīt (manual) 1 study 1.16 0.00 1.16 7.1.1.3.
platelets (manually) study 1 1.04 0.00 1.04 7.1.1.4.
sink rate of red (EGA) 1 study 0.76 0.00 0.76 7.1.1.5.
Leukocyte formula and erythrocyte morphology 1 study 1.76 0.00 1.76 7.1.1.6.
flowing blood in time after the Duke study 0.70 0.00 0.70 7.1.1.7 method 1.
Red vilkēd (LED) study of cell 1 4.58 0.00 4.58 7.1.1.8.
blood test with a three-part Blood analyser 1 discriminatory study 1.73 0.00 1.73 7.1.1.9.
retikulocīt automated haematology Analyzer in the investigation with 1 study 4.66 0.00 4.66 7.1.1.10.
blood analysis with five-part Blood analyser 1 discriminatory study 3.00 0.00 3.00 7.1.1.11.
blood analysis with five-part of the analyser and discriminatory blood red cells sink rate (EG) discovery 1 study 3.76 0.00 3.76 7.1.1.12.
blood analysis, determination of retikulocīt with five-part of the analyser and discriminatory blood red cells sink rate (EG) discovery 1 study 8.42 0.00 8.42 7.1.1.13.
blood analysis with five-part blood in the discriminatory anal, set retikulocīt za tor carrying manually and sink rate of red (EGA) determine capacity 1 study 4.92 0.00 4.92 7.1.2.
urine investigation 7.1.2.1.
physical examination 1 study 0.16 0.00 0.16 7.1.2.2.
protein (quantitative) study 1 1.24 0.00 1.24 7.1.2.3.
quantitative microscopy 1 sediment study 1.45 0.00 1.45 7.1.2.4.
urine analysis with strip (environmental level (pH), olbal dark matter, sugar, acetone, bilirubin, urobilinogēn, blood) 1 study 0.87 0.00 0.87 7.1.2.5.
analysis of urine with the strip, physical and mikroskopēšan study of sediment 1 2.16 0.00 2.16 7.1.2.6.
determination of specific weight of urine with 1 urometr study 0.18 0.00 0.18 7.1.3.
clinical investigation of likvor 1 the examination 2.51 0.00 2.51 7.1.4.
sputum examination 7.1.4.1.
clinical analysis of sputum examination 1 1.91 0.00 1.91 7.1.4.2.
mikobaktērij bakterioskopisk of investigation 1 study 2.32 0.00 2.32 7.1.5.
investigation of faecal 7.1.5.1.
koprogramm 1 the examination 1.82 0.00 1.82 7.1.5.2.
a study of latent blood 1 0.44 0.00 0.44 7.1.5.3.
bile pigments 1 study 0.40 0.00 0.40 7.1.5.4.
hidden blood in the teststrēmel (imūnhromatogrāfij) 1 study 1.10 0.00 1.10 7.1.6.
the serous cavities and the cyst fluid analysis in study 1 clinical 1.91 0.00 1.91 7.2.
biochemical studies 7.2.1.
blood investigation 7.2.1.1.
bilirubin, study group 1 1.75 0.00 1.75 7.2.1.2.
alanīnaminotransferāz 1 the examination 1.41 0.00 1.41 7.2.1.3.
aspartātaminotransferāz 1 the examination 1.41 0.00 1.41 7.2.1.4.
alkaline phosphatase 1 study 1.41 0.00 1.41 7.2.1.5.
Alpha-1 amilāz study 2.35 0.00 2.35 7.2.1.6.
gammaglutamil transferāz 1 the examination 1.73 0.00 1.73 7.2.1.7.
kreatīnkināz 1 the examination 2.22 0.00 2.22 7.2.1.8.
urea (bun) 1 study 1.43 0.00 1.43 7.2.1.9.
creatinine 1 study 1.43 0.00 1.43 7.2.1.10.
uric acid study 1.55 0.00 1.55 7.2.1.11 1.
protein (total) 1 study 1.06 0.00 1.06 7.2.1.12.
albumin 1 study 7.2.1.13 1.12 0.00 1.12.
protein fractions 1 study 4.36 0.00 4.36 7.2.1.14.
glucose blood study 0.97 0.00 0.97 7.2.1.15 1.
glucose loading test 1 study 3.31 0.00 3.31 7.2.1.16.
cholesterol total 1 study 1.46 0.00 1.46 7.2.1.17.
triglycerides study 1.79 0.00 1.79 7.2.1.18 1.
C-reactive protein (quantitative) study 2.61 0.00 2.61 7.2.1.19 1.
for 5.12 0.00 5.12 7.2.1.20 ferritīn 1 the examination.
by antistreptolizīn-0 (high quality) 1 study 1.73 0.00 1.73 7.2.1.21.
determination of ethanol by enzymatic study 4.50 0.00 4.50 7.2.1.22 1.
potassium 1 study 1.68 0.00 1.68 7.2.1.23.
sodium 1 study 1.68 0.00 1.68 7.2.1.24.
calcium 1 study 1.43 0.00 1.43 7.2.1.25.
study of iron 1 1.58 0.00 1.58 7.2.1.26.
Iron binding capacity study 2.25 0.00 2.25 1 7.2.1.27.
copper in the blood 1 study 2.97 0.00 2.97 7.2.1.28.
free (FT4) 1 tiroksīn study 7.2.1.29 4.06 0.00 4.06.
free (FT3) 1 trijodtironīn study 7.2.1.30 4.06 0.00 4.06.
the tireotrop hormone (TSH) 1 study 3.93 0.00 3.93 7.2.1.31.
Reduced Glutathione study 11.98 0.00 11.98 7.2.1.32 1.
rheumatoid factor (quality in tatīv) 1 study 1.52 0.00 1.52 7.2.1.33.
the high density lipopr-te (HDL) cholesterol INE 1 study 1.94 0.00 1.94 7.2.1.34.
low density lipoprotein (LDL) cholesterol study 2.44 0.00 2.44 7.2.1.35 1.
apolipoproteīn A1 1 study 2.81 0.00 2.81 7.2.1.36.
apolipoproteīn B 1 study 2.81 0.00 2.81 7.2.1.37.
soluble transferīn receptor study 6.43 0.00 6.43 7.2.1.38 1.
the cardiac troponin T (acute myocardial infarction Express) 1 study 5.29 0.00 5.29 7.2.1.39.
Myoglobin 1 study 4.89 0.00 4.89 7.2.1.40.
insulin study 4.57 0.00 4.57 7.2.1.41 1.
hyaluronic acid 1 study 10.51 0.00 10.51 7.2.1.42.
citokeratīn 18 (CK 18 neo-epitopes) 7.70 0.00 7.70 1 study 7.2.1.43.
cytochrome c 1 study 10.57 0.00 10.57 7.2.1.44.
endotoxin core antibody (quantitative) study 7.69 0.00 7.69 7.2.1.45 1.
nitrates/nitrites quantitative study 6.22 0.00 6.22 7.2.1.46 1.
blood gas and environmental level (pH) analysis study 12.25 0.00 12.25 7.2.1.47 1.
serum (plasma) getting 1 study 0.39 0.00 0.39 7.2.2.
a study of likvor 7.2.2.1.
chlorides 1 study 1.40 0.00 1.40 7.2.2.2.
protein (quantitative) study 1 7.2.2.3 0.79 0.00 0.79.
glucose (quantitative) study 1 0.79 0.00 0.79 7.2.3.
punktāt investigation (protein (total)) 1 study 1.06 0.00 1.06 7.2.4.
imūnhematoloģij studies of 7.2.4.1.
determination of blood group ABO system with planes method (dubultreakcij) (A and B antigen detection by direct reaction, anti-A and anti-B antibodies with the inverse reaction) 1 study 1.56 0.00 1.56 7.2.4.2.
rhesus factor (Rh (D)) signs with planes method (with two reagents) 1 study 1.64 0.00 1.64 7.2.4.3.
rhesus factor (Rh (D)) features detection geltehnik (with one reagent) 1 study 1.78 0.00 1.78 7.2.4.4.
not full antieritrocitār antibody screening geltehnik (ID card List/Coomb) 1 study 3.07 0.00 3.07 7.2.4.5.
determination of blood group ABO system with planes method (direct response) (A and B antigen with direct response) 1 study 0.86 0.00 0.86 7.2.4.6.
determination of blood group ABO and rhesus factor (Rh) system in geltehnik (A and B antigen detection by direct reaction, anti-A and anti-B antibodies with the inverse reaction, D Antigen) 1 study 3.74 0.00 3.74 7.2.4.7.
rhesus factor (Rh) system phenotype (CcE) and the determination of the Kell geltehnik 7.2.4.8 in study 1 5.68 0.00 5.68.

of the recipient and the donor's blood test in the individual compatibility Lab (ABO, rhesus factor (Rh) and other systems-geltehnik) 1 study 7.73 0.00 7.73 7.2.4.9.
a direct test of the anti-human globulin – (data) geltehnik (ID card List/Coomb) 1 study 1.97 0.00 1.97 7.2.5.
7.2.5.1 tests koaguloģij.
protrombīn index (INR) 1 study 1.62 0.00 1.62 7.2.5.2.
the activated partial tromboplastīn time (APTL) 1 study 1.79 0.00 1.79 7.2.5.3.
Fibrinogen 1 study 1.79 0.00 1.79 7.2.5.4.
Thrombin time 1 study 1.74 0.00 1.74 7.2.6.
urine investigation 7.2.6.1.
glukuronīd in urine 1 study 15.46 0.00 15.46 7.2.6.2.
protein (quantitative) study 1 0.79 0.00 0.79 7.2.6.3.
glucose (quantitative) study 1 0.79 0.00 0.79 7.2.6.4.
Alpha-1 amilāz study 2.35 0.00 2.35 7.2.6.5.
study of iron 1 1.58 0.00 1.58 7.2.6.6.
calcium 1 study 1.43 0.00 1.43 7.2.6.7.
urea (bun) 1 study 1.43 0.00 1.43 7.2.6.8.
1 study 1.43 0.00 1.43 creatinine 7.2.6.9.
uric acid study 1.55 0.00 1.55 7.2.6.10 1.
determination of ethanol by enzymatic study 4.50 0.00 4.50 7.2.6.11 1.
drugs and their derivatives ekspres diagnostic test (panel of four substances) 1 study 4.04 0.00 4.04 7.2.6.12.
drugs and their derivatives ekspres diagnostic test (panel of eight substances) 1 study 6.57 0.00 6.57 7.2.7.
testing with dry chemistry analyser REFLOTRON 7.2.7.1.
determination of cholesterol by dry chemistry analyser REFLOTRON 1 study 1.78 0.00 1.78 7.2.7.2.
bilirubin determination by dry chemistry analyser REFLOTRON 1 study 1.78 0.00 1.78 7.2.7.3.
alanīnminotransferāz (AL) with dry chemistry analyser REFLOTRON 1 study 1.78 0.00 1.78 7.2.7.4.
the aspartātaminotransf (S) determining rāz with dry chemistry analyser REFLOTRON 1 study 1.78 0.00 1.78 7.2.7.5.
determination of triglycerides with dry chemistry analyser REFLOTRON 1 study 2.01 0.00 2.01 7.2.7.6.
pankreātisk determination of amylase by dry chemistry analyser 1 study IV 2.23 0.00 2.23 REFLOTRON 7.2.7.7.
determination of glucose by dry chemistry analyser REFLOTRON IV 1 study 7.2.7.8 1.90 0.00 1.90.
high density lipoproteins (HDL)-cholesterol determination by dry chemistry analyser REFLOTRON 1 study 2.12 0.00 2.12 7.2.7.9.
determination of urea (bun) with dry chemistry analyser 1 study IV 2.17 0.00 2.17 REFLOTRON 7.2.7.10.
determination of the concentration of creatinine with dry chemistry analyser 1 study IV 2.09 0.00 2.09 REFLOTRON 7.2.7.11.
alpha-amylase activity detection with dry chemistry analyser REFLOTRON IV 1 study 2.43 0.00 2.43 7.2.7.12.
determination of potassium with dry chemistry analyser 1 study IV 2.23 0.00 2.23 REFLOTRON 7.2.7.13.
rāz-gammaglutamīntransf (GG) activity detection with dry chemistry analyser REFLOTRON IV 1 study 2.02 0.00 2.02 7.3.
parasitological studies 7.3.1.
blood parasite (malaria, filariidoz) thick drops of 1 study 7.36 0.00 7.36 7.3.2.
Malaria blood smear pazmodij 1 the examination 8.27 0.00 8.27 7.3.3.
Blood of Plasmodi Ag (imūnhromatogrāfij) 1 study 4.91 0.00 4.91 7.3.4.
analysis on the helminth (Kato) 1 study 1.58 0.00 1.58 7.3.5.
scrape of the perian folds in the layman spalīš eggs 1 study 0.91 0.00 0.91 7.3.6.
investigation of enterobioz with adhesive tape method 1 study 1.86 0.00 1.86 7.3.7.
Pneumocyst a jiroveci (carini) Ag (IF)-Pneumocyst by jiroveci (carini) Antigen with indirect imūnfluorescenc microscopy study of 1 of 13.60 0.00 13.60 7.3.8.
Cryptosporidium Ag with faeces (ELISA)-Cryptosporidium anti gene determination by immune enzymatic reaction 1 study 5.99 0.00 5.99 7.3.9.
lamblij and helminth determination of bile in preparation for native and sediment (three servings) 1 study 6.58 0.00 6.58 7.3.10.
Protozoa cyst and HAL min you investigation eggs with enrichment (concentration) method 4.13 0.00 4.13 7.3.11 1 study.
scabbers mite, dziedzerērc 1 the examination 5.28 0.00 5.28 7.3.12.
helmint and determination of their snippet 1 study 2.31 0.00 2.31 7.3.13.
intestinal protozoa parasite detection in natīv preparation 1 study 7.3.14 2.79 0.00 2.79.
Anti-Toxocar-Canis IgG (ELISA) immunoglobulin G antibodies to the class of cērmj larvae of the dog study 4.26 0.00 4.26 7.3.15 1.
Anti-Trichinella spiralis IgG (ELISA) imūngl the bulīn G-class antibody against Trichinella examination 1 4.26 0.00 4.26 7.3.16.
Echinococcus anti-IgG (ELISA) species immune globulin G-class antibodies against ehinokok species (e. granulos, e. multilokular) 1 study 7.81 0.00 7.81 7.3.17.
Echinococcus granulosus anti-IH-HA antibody reaction to the study of the unicameral ehinokok 1 8.80 0.00 8.80 7.3.18.
The compatible lambli (Ag faeces) (ELISA)-lamblij Antigen from na to imūnfermentatīv response 1 study 7.3.19 5.99 0.00 5.99.
Entamoeb-anti-hystolitic-IH-the gl IE Nations hems response of antibodies against Entamoeb hystolitic (the Amoeba dysentery) 1 study 10.76 0.00 10.76 7.3.20.
Entamoeb hystolitic Ag in the faeces (ELISA) – the Amoeba dysentery Antigen with imūnfermentatīv response 1 study 6.61 0.00 6.61 7.3.21.
Anti-IgG of Taenia (ELISA) immunoglobulin G antibody class-determined carrying the tapeworm larvae to pig 1 study 8.67 0.00 8.67 7.3.22.
Cysticercos by WB-cisticerk IgG immunoglobulin G antibodies to transmit class of authorisations requested by Western blot reaction 1 study 35.17 0.00 35.17 7.3.23.
Toxocar WB toksokar immunoglobulin G IgG-class antibodies to transmit of authorisations requested by Western blot reaction 1 study 31.72 0.00 31.72 7.3.24.
Trichinae Trichinella WB IgG-class antibody immunoglobulin G approval by Western blot reaction 1 study 35.17 0.00 35.17 7.3.25.
Echinoccoc-WB IgG immunoglobulin G ehinokok-class antibody transmit of authorisations requested by Western blot reaction 1 study 35.17 0.00 35.17 7.4.
the veneroloģisk investigation castings 7.4.1.
Chlamidi trachomatis Antigen (IFA)-Chl's midi trachomatis anti gene determination by immune fluorescence reaction 1 study 4.68 0.00 4.68 7.4.2.
Chlamidi trachomatis Antigen (ELISA) – Chlamidi trachomatis Antigen with imūnfermentatīv response 1 study 8.89 0.00 8.89 7.4.3.
Trichomonas from vaginal set in preparation of the study natīv 1 1.21 0.00 1.21 7.4.4.
gynecological smears in 1 study 2.10 0.00 2.10 7.4.5.
syphilis-diagnosis (of Treponema pallidum) HA (TPH) 1 study 2.10 0.00 2.10 7.4.6.
syphilis-diagnosis (of Treponema pallidum) HA (TPH) by titration 1 study 4.41 0.00 4.41 7.4.7.
Demonstration of Treponema pallidum by dark field microscopy 1 study 1.65 0.00 1.65 7.4.8.
syphilis Diagnostics-reagīn of precipitation (RPR) 1 study 1.46 0.00 1.46 7.4.9.
syphilis Diagnostics-reagīn of precipitation (RPR) with titration 1 study 4.51 0.00 4.51 7.4.10.
plating on Mycoplasma 1 study 6.73 0.00 6.73 7.4.11.
plating on ureaplazm 1 the examination 6.73 0.00 6.73 7.4.12.
plating on gonococcal (positive) 1 study 10.40 0.00 10.40 7.4.13.
plating on gonococcal (negative) 1 study 6.75 0.00 6.75 7.4.14.
reagīn precipitin reaction (RPR) 1 hour study 4.28 0.00 4.28 7.4.15.
sexually transmitted diseases (STDs) in the film the hour 1 study 3.75 0.00 3.75 7.4.16.
certificate to the syphilis study 1 3.05 0.00 3.05 7.4.17.
certificate-duplicate for syphilis to 1 study 3.62 0.00 3.62 7.4.18.
Chlamidi trachomatis Antigen confirmatory test (ELISA) – Chlamidi trachomatis Antigen approval with imūnfermentatīv response 1 study 16.02 0.00 16.02 7.4.19.
Mycoplasma or ureaplazm determination of sensitivity to antibiotics study 5.79 0.00 5.79 1 7.5.
hepatitis diagnostic 7.5.1.
Anti-HAV: antibody (ELISA) against hepatitis A virus through a study of the reaction of 1 imūnfermentatīv 5.50 0.00 5.50 7.5.2.
Anti-HAV IgM (ELISA)-immune globulin M class against viral hepatitis A antibody determination by immune enzymatic reaction 1 study 6.30 0.00 6.30 7.5.3.
HAVE Ag (ELISA) – viral hepatitis A Antigen with imūnfermentatīv response 1 study 7.75 0.00 7.75 7.5.4.
HBS Ag (ELISA) – viral hepatitis B surface antigen with imūnfermentatīv response 1 study 3.43 0.00 3.43 7.5.5.
HBS Ag confirmatory (ELISA) – viral hepatitis B surface antigen positive test 1 study 8.28 0.00 8.28 7.5.6.
Anti-HBS quantitative antibody (ELISA) against viral hepatitis B-quantum of tatīv detection with imūnfermentatīv response 1 study 7.55 0.00 7.55 7.5.7.
Anti-HBc antibody (ELISA) – against the hepatitis B virus core Antigen immuno-enzymatic reaction with 1 study 6.05 0.00 6.05 7.5.8.

Anti-HBc IgM (ELISA)-immune globulin M class antibody against viral hepatitis B core Antigen with imūnfermentatīv response 1 study 6.47 0.00 6.47 7.5.9.
HBE Ag (ELISA) – viral hepatitis B E Antigen with imūnfermentatīv response 1 study 7.52 0.00 7.52 7.5.10.
Anti-HBE (ELISA) – anti substance against viral hepatitis B E anti gene detection with imūnfermentatīv response 1 study 7.52 0.00 7.52 7.5.11.
Anti-HCV (ELISA) – antibody against viral hepatitis C with imūnfermentatīv response 1 study 6.80 0.00 6.80 7.5.12.
Anti-HCV positive test (WB) – antibody against viral hepatitis C approval by Western blot reaction 1 study 44.57 0.00 44.57 7.5.13.
HCV RNA (PCR) – viral hepatitis C ribonukleīnskāb detection with polymerase chain reaction 1 study 51.30 0.00 51.30 7.5.14.
HD Ag (ELISA)-Hepatitis delta virus Antigen immune enzymatic reaction with 1 study 5.95 0.00 5.95 7.5.15.
Anti-HD (ELISA) immunoglobulin IgM-class antibodies against M Hepatitis delta virus detection with imūnfermentatīv response 1 study 5.95 0.00 5.95 7.5.16.
AFP (ELISA)-alpha-fetoproteīn detection with imūnfermentatīv response 1 study 4.69 0.00 4.69 7.5.17.
HBS Ag (ELISA)-Other viral hepatitis B surface antigen detection with imūnfermentatīv quick response two hours 1 study 9.32 0.00 9.32 7.5.18.
Anti-HAV IgM, the Other (ELISA) immunoglobulin M antibodies against vīrushep of class a cue (A) quick determination by the response to the imūnfermentatīv tion two hours 1 study 12.37 0.00 12.37 7.5.19.
Anti-HBc (ELISA) – Other antibodies against hepatitis B virus core Antigen two hours 1 study 12.19 0.00 12.19 7.5.20.
Anti-HCV (ELISA) – Other antibodies against viral hepatitis C quick determination by immune enzymatic reaction within two hours of study 1 13.02 0.00 13.02 7.5.21.
HBS Ag certificate (ELISA) – viral hepatitis B surface antigen with immune enzymatic reaction 1 study 7.5.22 5.18 0.00 5.18.
HBS Ag certificate (ELISA) – viral hepatitis B surface antigen with immune enzymatic reaction within two hours of study 1 8.28 0.00 8.28 7.5.23.
Anti-HD (ELISA) immunoglobulin IgG-class antibodies against G Hepatitis delta virus detection with imūnfermentatīv response 1 study 5.95 0.00 5.95 7.5.24.
HCV RNA load (PCR) – viral hepatitis C determination of ribonukleīnskāb by polymerase chain reaction 1 study 7.5.25 105.34 0.00 105.34.
HCV genotipēšan (kulār of clones in an amortisation mole) – hepatitis C genotype of virus detection study 147.89 0.00 147.89 7.5.26 1.
HBV DNA (PCR) load-viral hepatitis B dezoksiribonukleīn acid determination by polymerase chain reaction study 88.83 0.00 88.83 7.5.27 1.
Anti-HEV IgM (ELISA) immunoglobulin M antibodies against viral hepatitis of class E with imūnfermentatīv response 1 study 12.87 0.00 12.87 7.5.28.
Anti-HEV IgG (ELISA) immunoglobulin G antibodies against viral hepatitis of class E with imūnfermentatīv response 1 study 9.71 0.00 9.71 7.6.
HIV/AIDS Diagnostics 7.6.1.
Anti-HIV 1/2 antibody against the quick method — human immunodeficiency virus 1 and 2 with quick determination method 1 study 4.22 0.00 4.22 7.6.2.
Anti-HIV 1/2 to the certificate (ELISA) – antibody against human immunodeficiency virus 1 and 2 with imūnfermentatīv response 1 study 10.01 0.00 10.01 7.6.3.
Anti-HIV 1/2 with certificate and duplicate (ELISA) – antibody against human immunodeficiency virus 1 and 2 with imūnfermentatīv response 1 study 10.70 0.00 10.70 7.6.4.
Anti-HIV 1/2 with the quick method, and a certificate – antibody against human immunodeficiency virus 1 and 2 with quick determination method 1 study 11.73 0.00 11.73 7.6.5.
Anti-HIV 1/2 with the quick method, the certificates and duplicates – antibody against human immunodeficiency virus 1 and 2 with quick determination method 1 study 12.42 0.00 12.42 7.6.6.
Anti-HIV 1/2 antibody (ELISA) against human immunodeficiency virus 1 and 2 determination by immune enzymatic reaction 1 study 4.53 0.00 4.53 7.6.7.
HIV load (HIV RNA Kwan.) (PCR) – HIV RNA quantification with PCR-1 study 109.50 0.00 109.50 7.6.8.
Anti-HIV 1/2 Ag (ELISA) and HIV-antibody against at the human immunodeficiency virus 1 and 2 and the human imūndef virus Antigen deficits through imūnfer menu tatīv response 1 study 4.53 0.00 4.53 7.6.9.
Anti-HIV-1 and/or 2 the confirmatory test for antibodies against the WB-human immunodeficiency virus 1 and 2 approval by Western blot reaction 1 examination 31.36 0.00 31.36 7.6.10.
Ag (ELISA)-HIV human immunodeficiency virus Antigen with imūnfer mentatīv response 1 study 15.62 0.00 15.62 7.6.11.
HIV Ag confirmatory (ELISA to neutralize the tion), human immunodeficiency virus Antigen approval with imūnfermentatīv reaction with neutralization study 7.6.12 40.23 0.00 40.23 1.
HIV (human immunodeficiency virus) genotipēšan the umbrella term of Reza (the equestrian sekven) 1 study 441.62 0.00 441.62 7.7.
immunological studies 7.7.1.
imūnstatus-determination of lymphocyte imunofenotip quantitative (absolute number,%) (CD3/CD4/CD8 CD3, CD16 + CD3 CD56 CD19, HLA-DR, HLA-DR CD3/), 1 study flow citometrij 29.92 0.00 29.92 7.7.2.
t-lymphocytes in the imunofenotip determination (absolute number,%) (CD3/CD 4, CD3/CD8), flow citometrij study 1 24.54 0.00 24.54 7.7.3.
imūnregulējoš cell: CD195 (CCR5), flow citometrij study 1 8.91 0.00 8.91 7.7.4.
the human Antigen B count tipēšan by molecular hybridization (HLA B-human leucocyt antigen of B) 1 study 107.33 0.00 107.33 7.8.
Herpes group virus infection Diagnostics 7.8.1.
Anti-CMV IgG quantitative (ELISA) immunoglobulin G antibody against another class through the megalovīrus reaction imūnfermentatīv 1 the examination 7.97 0.00 7.97 7.8.2.
Anti-CMV IgM (ELISA) immunoglobulin M antibodies against citom of the class galovīrus through imūnfermentatīv response 1 study 6.52 0.00 6.52 7.8.3.
Anti-HSV IgM (ELISA)-immune globulin M class antibodies against herpes simplex virus type 1 and 2 with imūnfermentatīv response 1 study 6.10 0.00 6.10 7.8.4.
HSV1/2 Ag IF – herpes simplex virus type 1 and 2 Antigen determination by immune fluorescence microscopy study of 1 7.89 0.00 7.89 7.8.5.
Anti-IgG quantitative HSV1/2 (ELISA) immunoglobulin G class antibodies against herpes simplex type 1 and 2 determination with imūnfer mentatīv response 1 study 6.74 0.00 6.74 7.8.6.
Anti-VZV (HZV) IgM (ELISA) immunoglobulin M antibodies against Varicell of the class (or herpes zoster) zoster virus detection with imūnfermentatīv response 1 study 7.45 0.00 7.45 7.8.7.
Anti-VZV (HZV) IgG quantitative (ELISA) immunoglobulin G antibody-class against the Varicell (or herpes zoster) zoster virus identification with imūnfermentatīv response 1 study 7.8.8 8.82 0.00 8.82.
Anti-CMV IgG aviditāt (ELISA) immunoglobulin G antibodies against citomegalovīrus of class aviditāt with imūnfermentatīv determination of reaction 1 study 8.79 0.00 8.79 7.8.9.
CMV DNA quantitative (PCR-RL) – the citomegol virus desoxy ri bonukleīn acid (CMV DNA) identification by PCR in real time study 1st 44.63 0.00 44.63 7.8.10.
CMV DNA (PCR) – another quality the megal dezoksiribonukleīn acid of virus (CMV DNA) identification with polymerase chain reaction study 15.88 0.00 15.88 7.8.11 1.
Anti-EBV EA (ELISA)-IgM immune class of globe PIA M antibodies against Epstein-Barr virus early Antigen determination by immune fermen tatīv response 1 study 7.8.12 5.18 0.00 5.18.
Anti-EBV EA IgG quantitative (ELISA) immunoglobulin G antibody against Epstein present ses-Barr virus early Antigen ta light detection of quantum with immune enzymatic reaction 1 study 7.8.13 5.18 0.00 5.18.
Anti-VCA IgM EBV (ELISA)-a PIA imūnglob M class of antibodies against Epstein-Barr virus Antigen detection in skin of immune enzymatic reaction study 4.95 0.00 4.95 7.8.14 1.
Anti-VCA IgG EBV quantitatively (ELISA) immunoglobulin G antibody against Epstein in class-Barra viral skin Antigen determination with imūnfermentatīv response 1 study 6.93 0.00 6.93 7.8.15.
Anti-EBV IgG quantitative EBN (ELISA) immunoglobulin G antibody against Epstein in class-Barr virus nuclear antigen detection of quantum tatīv imūnfermentatīv response 1 study 6.46 0.00 6.46 7.8.16.
Anti-EBV IgM, WB-immunoglobulin M antibody against Epstein in class-Barra viral validation by Western blot reaction study 31.67 0.00 31.67 7.8.17 1.
Anti-EBV IgG immunoglobulin G, WB-class antibodies against Epstein-Barr virus transmit of authorisations requested by Western blot reaction study 31.67 0.00 31.67 7.8.18 1.
EBV DNA quantitative (PCR-RL), Epstein-Barr virus in bonukleīnskāb dezoksir (DNA) identification by PCR in real time study 1st 44.63 0.00 44.63 7.8.19.

EBV DNA (PCR) quality-Epstein-Barr virus (EBV) dezoksiribonukleīn acid (DNA) detection quality with polymerase chain reaction study 15.88 0.00 15.88 7.8.20 1.
HSV 1/2 DNA quantitative (PCR-RL)-Herpes simplex type 1 and 2 the discovery of acid nuclein dezoksirib Kwan titatīv by polymerase chain reaction real time study 1st 44.63 0.00 44.63 7.8.21.
HSV1/2 DNA (PCR) quality – herpes simplex 1 and 2, subtip dezok sirib of the nucleic acid (DNA) of high quality with poly merāz chain reaction 1 study 15.88 0.00 15.88 7.8.22.
herpes virus isolation and tipēšan (tissue culture) study 7.8.23 1 23.71 0.00 23.71.
immunoglobulin M antibodies against T.O.R.C.H. class group infections (rubella of toks, plazmoz, citomegalovīrus and herpes infections) apstiprinā0šan with Western blot reaction study 31.67 0.00 31.67 7.8.24 1.
VZV (HZV) DNS Kwan titatīv (PCR-RL) – Varicell's (or herpes zoster) zoster virus dezoksirib nucleic acid from the said horse with quantitative polymerase chain reaction real time study 44.63 0.00 44.63 7.8.25 1.
VZV (HZV) DNA (PCR) – quality of Varicell zoster (zoster or Herpes) virus detection dezribonukleīnskāb by polymerase chain reaction 1 study 15.88 0.00 15.88 7.9.
respiratory viral infection Diagnostics 7.9.1.
(A) influenza virus Antigen by imūnfluorescenc 1 the examination 8.24 0.00 8.24 7.9.2.
Influenza virus b Antigen with imūnfluorescenc 1 the examination 8.24 0.00 8.24 7.9.3.
Influenza virus a/B ribonukleīnskāb (RNA) of high quality with polymerase chain reaction in study 1, 27.60 0.00 27.60 7.9.4.
Influenza virus a/B ribonukleīnskāb (RNA) of high quality with polymerase chain reaction real time study 1st 44.63 0.00 44.63 7.9.5.
A flu virus detection quality with a subtip polymerase chain response to the information, if A flu virus RNA (RNA) is positive 1 study 27.60 0.00 27.60 7.9.6.
A flu virus subtip discovery with polymerase chain reaction in real time if A flu virus RNA (RNA) is positive 1 study 44.63 0.00 44.63 7.9.7.
paragrip viral antigen detection by imūnfluorescenc 1 the examination 8.19 0.00 8.19 7.9.8.
paragrip virus tipēšan with imūnfluorescenc 1 the examination 15.26 0.00 15.26 7.9.9.
adenovīrus the Antigen with imūnfluorescenc 1 the examination 8.22 0.00 8.22 7.9.10.
adenovīrus isolation from clinical material 1 study 7.9.11 23.33 0.00 23.33.
complement fixation detection of adenovīrus 1 the examination 8.05 0.00 8.05 7.9.12.
respirators in virus Antigen sincitiāl (RSV, Ag) detection with imūnfluorescenc 1 study 8.24 0.00 8.24 7.9.13.
Anti-RSV IgM (ELISA) immunoglobulin M antibodies against respiratory class in virus detection with sincitiāl imūnfermentatīv response 1 study 6.43 0.00 6.43 7.9.14.
haemagglutination (HA) inhibition with one Antigen (influenza A/H1N1, A/H3N2, B, paragrip I, II, III type) 1 study 7.16 0.00 7.16 7.9.15.
influenza virus isolation in tissue culture and tipēšan 1 the examination 23.12 0.00 23.12 7.9.16.
the human meta pneumo (hMPV) determination by imūnfluorescenc 1 the examination 9.74 0.00 9.74 7.10.
acute viral gastroenteritis diagnostic 7.10.1.
adenovīrus Ag (ELISA)-adenovīrus with imūnfermentatīv the Antigen response 1 study 7.06 0.00 7.06 7.10.2.
rotavirus Ag (ELISA)-rotavirus Antigen with imūnfermentatīv response 1 study 7.06 0.00 7.06 7.10.3.
astrovīrus Ag (ELISA)-astrovīrus with imūnfermentatīv the Antigen response 1 study 7.06 0.00 7.06 7.10.4.
programme identifying norovirus Ag (ELISA) – a programme identifying norovirus Antigen with imūnfermentatīv response 1 study 9.46 0.00 9.46 7.10.5.
programme identifying norovirus ribonukleīnskāb (RNA) of the detection quality with polymerase chain reaction 1 study 15.88 0.00 15.88 7.11.
7.11.1 involved infections Diagnostics.
the withdrawal and the involved tipēšan 1 study 33.10 0.00 33.10 7.11.2.
complement fixation detection of 1 the study involved 8.05 0.00 8.05 7.11.3.
involved in RNA (PCR-RL) quantitative-of ribonukleīnskāb of the determination involved with poly merāz chain reaction real time study 1st 44.63 0.00 44.63 7.11.4.
involved in RNA (PCR)-the quality of the identification of the involved ribonukleīnskāb by polymerase chain reaction 1 study 15.88 0.00 15.88 7.11.5.
the distribution of involved tissue culture study 23.33 0.00 23.33 7.11.6 1.
neutralization reaction tissue culture with poliovīrus type 1 study 8.67 0.00 8.67 7.11.7.
Anti-a antibodies involved with imūnfermentatīv response 1 study 8.15 0.00 8.15 7.12.
tick-transmitted infection diagnosis 7.12.1.
Anti-TBE IgM likvor (ELISA) immunoglobulin M antibodies against ticks class encephalitis virus detection with imūnfermentatīv response 1 study 5.97 0.00 5.97 7.12.2.
Anti Borrelia burgdorferi IgG immune globulin (WB) – (G) class of antibodies against Borrelia burgdorferi approval by Western blot reaction 1 study 24.02 0.00 24.02 7.12.3.
Anti-TBE IgM (ELISA)-imūngl bulīn-M class of antibodies against the virus of equine encephalomyelitis for ticks enc detection with imūnfermentatīv response 1 study 6.90 0.00 6.90 7.12.4.
Anti-TBE IgG (ELISA)-immune globulin G class of antibodies to tick-borne encephalitis virus detection with imūnfermentatīv response 1 study 7.12.5 7.71 0.00 7.71.
Anti-Ehrlichi (Anaplasm) with imūnfluorescenc in study 1 IgG 12.67 0.00 12.67 7.12.6.
Anti-Ehrlichi (Anaplasm) with the IgM 1 study 12.67 0.00 12.67 7.12.7 imūnfluorescenc.
Anti Borrelia burgdorferi IgM (ELISA) immunoglobulin M antibody class against Borrelia burgdorferi determination by imūnfermentatīv response 1 study 6.80 0.00 6.80 7.12.8.
Anti Borrelia burgdorferi IgG quantitative (ELISA) immunoglobulin G class antibodies against Borrelia burgdorferi determination by imūnfermentatīv response 1 study 7.19 0.00 7.19 7.12.9.
Anti Borrelia burgdorferi IgM immune globulin (WB)-M class against Borrelia burgdorferi antibodies by Western blot confirmation response 1 study 7.12.10 24.02 0.00 24.02.
Borrelia DNA (PCR-RL)-dezoksir of the bonukleīnskāb of Borrelia detection with polymerase chain reaction real time study 1st 49.57 0.00 49.57 7.13.
rare and imported infections the serological and molecular biological diagnostic 7.13.1.
Anti-virus IgM Hunt (ELISA) immunoglobulin M antibodies against the hunt class virus detection with imūnfermentatīv response 1 study 15.56 0.00 15.56 7.13.2.
Anti-Hunt (ELISA) immunoglobulin IgG-class antibodies against G Hunt virus detection with imūnfermentatīv response 1 study 16.99 0.00 16.99 7.13.3.
Anti-IgM burett of Coxiell (Q fever, ELISA) immunoglobulin M antibodies against Coxiell of the class of antigens by burnett imūnfermentatīv response 1 study 16.32 0.00 16.32 7.13.4.
Anti-IgG burnett of Coxiell (Q fever, ELISA) immunoglobulin G class anti-Coxiell of substances against burnett in the Antigen detection with imūnfermentatīv response 1 study 16.99 0.00 16.99 7.13.5.
The pneumophil's of anti-IgM Legionell (ELISA) immunoglobulin M antibodies against class a pneumophil discovery with Legionell imūnfermentatīv response 1 study 9.44 0.00 9.44 7.13.6.
Anti-pneumophil of IgG Legionell (ELISA) immunoglobulin G antibody against the class of the pneumophil discovery with Legionell imūnfermentatīv response 1 study 9.44 0.00 9.44 7.13.7.
Anti-Deng-IgM (ELISA)-immune globulin M class of antibodies against the virus by Deng imūnfermentatīv response 1 study 12.45 0.00 12.45 7.13.8.
Anti-Deng-IgG (ELISA) immunoglobulin G antibody-class against the virus by Deng imūnfermentatīv response 1 study 12.45 0.00 12.45 7.13.9.
Deng is RNA (PCR-RL)-Deng-ribonukleīnskāb detection of virus by PCR in real time study 1st 63.10 0.00 63.10 7.13.10.
Anti-Puumal-IgM (ELISA)-Globe of PIA M immune class of antibodies against Puumal virus by immune enzymatic reaction study 16.10 0.00 16.10 7.13.11 1.
Anti-West-Nile (ELISA) IgM immune globulin M-class antibody against West Nile virus-detection with imūnfermentatīv response 1 study 12.45 0.00 12.45 7.13.12.
Anti-West-Nile-imūnglob IgG (ELISA) of PIA G class antibody against West Nile virus-detection with immune enzymatic reaction study 12.45 0.00 12.45 7.13.13 1.
West-Nile-RNA (PCR RL) West-Nile virus detection ribonukleīnskāb by polymerase chain reaction real time study 1st 63.03 0.00 63.03 7.13.14.
Anti-SARS-CoV IgM (ELISA) immunoglobulin M antibodies against SARS class CoV by imūnfermentatīv response 1 study 11.73 0.00 11.73 7.13.15.
Anti-SARS-CoV IgG (ELISA) immunoglobulin G antibodies against SARS class CoV by imūnfermentatīv response 1 study 11.73 0.00 11.73 7.13.16.
SARS CoV (PCR RL) – SARS CoV ribonukleīn acid detection with polymerase chain reaction real time study 1st 63.03 0.00 63.03 7.14.

various infections disease serological and molecular biological diagnostic 7.14.1.
Anti-rubella IgM (ELISA)-immune globulin M class of antibodies against rubella virus detection with imūnfermentatīv response 1 study 8.82 0.00 8.82 7.14.2.
Anti-rubella quantitative IgG (ELISA) immunoglobulin G antibodies against rubella class viral quantification with imūnfermentatīv response 1 study 7.69 0.00 7.69 7.14.3.
Anti-Mycoplasma pneumoniae IgM (ELISA) – immune to PIA M globe class antibody against Mycoplasma pneumoniae determination by immune enzymatic reaction 1 study 7.14.4 7.25 0.00 7.25.
Anti-Mycoplasma pneumoniae IgG (ELISA) immunoglobulin G antibody against Mycoplasma class pneumoniae with imūnfermentatīv response 1 study 7.48 0.00 7.48 7.14.5.
Anti-Chlamydia pneumoniae IgM (ELISA) immunoglobulin M antibodies against Chlamydia class pneumoniae with imūnfermentatīv response 1 study 7.82 0.00 7.82 7.14.6.
Anti-Chlamydia pneumoniae IgG quantitative (ELISA) immunoglobulin G antibody against Chlamydia class pneumoniae with imūnfermentatīv response 1 study 7.82 0.00 7.82 7.14.7.
Anti-Toxoplazm (ELISA) of IgM-class antibodies of immunoglobulin M determination of the imūnfermentatīv against Toxoplazm response 1 study 6.51 0.00 6.51 7.14.8.
Anti-Toxoplazm IgG (quantitative) (ELISA) immunoglobulin G antibodies against Toxoplazm of class identification with imūnfermentatīv response 1 study 5.36 0.00 5.36 7.14.9.
Anti-Toxoplazm IGA (ELISA) immunoglobulin A antibodies against Toxoplazm of class determination with imūnfermentatīv manmad reaction study 1 4.98 0.00 4.98 7.14.10.
Anti-Toxoplazm IgG aviditāt (ELISA) immunoglobulin G antibody against Toxoplazm classes in the aviditāt detection with manmad imūnfermentatīv response 1 study 8.79 0.00 8.79 7.14.11.
Anti-Rubeol (ELISA) of IgM-class antibodies of immunoglobulin M against measles virus detection with imūnfermentatīv response 1 study 9.25 0.00 9.25 7.14.12.
Anti-Rubeol IgG quantitative (ELISA) immunoglobulin G antibody against measles class viral quantification with imūnfermentatīv response 1 study 9.79 0.00 9.79 7.14.13.
measles (Rubeol) virus isolation in tissue culture study 21.84 0.00 21.84 7.14.14 1.
Anti-parvovīrus-B19 IgM (ELISA) immunoglobulin M antibodies against parvovīrus of the class with imūnfermentatīv B19 reaction 1 study 7.60 0.00 7.60 7.14.15.
Parvovīrus B19 IgG Anti-a quantitative (ELISA) immunoglobulin G antibody against parvovīrus classes in the tatīv of quantum B19 set with immune enzymatic reaction study 7.92 0.00 7.92 7.14.16 1.
papilloma virus (low and high risk of oncogenes) determination by hybridisation 1 study 40.78 0.00 40.78 7.14.17.
Anti-Diphteri (ELISA) of Toxoid IgG immunoglobulin G antibody-class against the Toxoid imūnfermentatīv Diphteri by reaction 1 study 7.07 0.00 7.07 7.14.18.
Anti-IgM Mump (ELISA) immunoglobulin M antibodies against mumps class virus detection with imūnfermentatīv response 1 8.42 0.00 8.42 7.14.19 of the study.
Anti-IgG by Mump (ELISA) immunoglobulin G antibody-class against mumps virus detection with imūnfermentatīv response 1 study 7.83 0.00 7.83 7.14.20.
papilloma virus (PCR) (low and high risk of oncogenes) identification with polymerase chain reaction 1 study 15.88 0.00 15.88 7.15.
bacteriological studies 7.15.1.
bacteriological analysis 7.15.1.1.
blood – with the conventional method (negative) 1 study 10.06 0.00 10.06 7.15.1.2.
blood-with automatic system (negative) 1 study 11.22 0.00 11.22 7.15.1.3.
blood – with the conventional method (positive) 1 study 14.62 0.00 14.62 7.15.1.4.
blood-with automatic system (positive) 1 study 16.42 0.00 16.42 7.15.1.5.
the lumbar punktāt (negative) 1 study 9.48 0.00 9.48 7.15.1.6.
the lumbar punktāt, without isseri the serological detection of n. meningitidis tipēšan (positive) 1 study 19.35 0.00 19.35 7.15.1.7.
the punktāt – with a lumbar isseri meningitidis serological tipēšan of (positive) 1 study 18.13 0.00 18.13 7.15.1.8.
plating of the neck – Not the isseri meningitidis (negative) 1 study 5.26 0.00 5.26 7.15.1.9.
plating of the neck – without isseri the serological detection of n. meningitidis tipēšan (positive) 1 study 10.94 0.00 10.94 7.15.1.10.
plating of the neck – with the serological detection of n. meningitidis tipēšan isseri (positive) 1 study 16.61 0.00 16.61 7.15.1.11.
urine (negative) 1 study 7.57 0.00 7.57 7.15.1.12.
urine (positive) 1 study 13.55 0.00 13.55 7.15.1.13.
bile (negative) 1 study 7.55 0.00 7.55 7.15.1.14.
bile (positive) 1 study 14.62 0.00 14.62 7.15.1.15.
pus, discharge, punktāt, rinse waters (negative) 1 study 11.89 0.00 11.89 7.15.1.16.
pus, discharge, punktāt, rinse waters (positive) 1 study 15.40 0.00 15.40 7.15.1.17.
sputum (negative) 1 study 6.01 0.00 6.01 7.15.1.18.
sputum (positive) 1 study 16.39 0.00 16.39 7.15.1.19.
plating of the neck – beta haemolytic streptococci (negative) 1 study 8.58 0.00 8.58 7.15.1.20.
plating of the neck – beta haemolytic streptococci (positive) 1 study 10.93 0.00 10.93 7.15.1.21.
plating on different materials – Staphylococcus aureus (negative) 1 study 4.44 0.00 4.44 7.15.1.22.
plating on different materials – the woven Staphyl aureus (positive) 1 study 5.43 0.00 5.43 7.15.1.23.
the culture of the throat and nose, Corynebacterium diphtheriae the – (negative) 1 study 9.64 0.00 9.64 7.15.1.24.
the culture of the throat and nose, Corynebacterium diphtheriae-(positive) 1 study 14.28 0.00 14.28 7.15.1.25.
the culture of the throat and nose, Corynebacterium diphtheriae, the Unifi ed system (positive) 1 study 14.21 0.00 14.21 7.15.1.26.
stools – Shigella, salmonella (negative) 1 study 6.32 0.00 6.32 7.15.1.27.
stools – Shigella, salmonella, with the unified system (positive identification to serotype) 1 study 12.18 0.00 12.18 7.15.1.28.
-selection of stools Escherichia (negative) 1 study 7.20 0.00 7.20 7.15.1.29.
-selection of stools Escherichia (positive) 1 study 9.57 0.00 9.57 7.15.1.30.
stools-Escherichia coli 0157 (negative) 1 study 6.10 0.00 6.10 7.15.1.31.
stools-Escherichia coli 0157 (positive) 1 study 11.89 0.00 11.89 7.15.1.32.
different materials-enterobacteriaceae (negative) 1 study 6.91 0.00 6.91 7.15.1.33.
different materials-enterobacteriaceae (positive) 1 study 8.60 0.00 8.60 7.15.1.34.
materials (faeces, urine from the neck) – the genus Yersinia bacteria (negative) 1 study 6.14 0.00 6.14 7.15.1.35.
materials (faeces, urine from the neck)-Yersinia genus bacteria, with the conventional method (positive) 1 study 14.66 0.00 14.66 7.15.1.36.
materials (faeces, urine from the neck)-Yersinia genus bacteria – identification with a unified system (positive) 1 study 9.56 0.00 9.56 7.15.1.37.
plating of different materials to the genus Candida fungi (negative) 1 study 4.07 0.00 4.07 7.15.1.38.
plating from the neck to the genus Candida fungi (positive) study 1 7.64 0.00 7.64 7.15.1.39.
materials (faeces, urine, the lumbar punktāt, blood)-bacteria of the genus Campylobacter (negative) 1 study 6.67 0.00 6.67 7.15.1.40.
materials (faeces, urine, the lumbar punktāt, blood), Campylobacter bacteria in the genus with species identification of up-with the unified system (positive) 1 study 21.28 0.00 21.28 7.15.1.41.
anaerobic micro-organisms (negative) 1 study 11.71 0.00 11.71 7.15.1.42.
anaerobic micro-organisms: the identification with the unified system (positive) 1 study 20.72 0.00 20.72 7.15.1.43.
Vibrio cholerae stools – (negative) 1 study 6.44 0.00 6.44 7.15.1.44.
Vibrio cholerae stools – (positive) 1 study 8.54 0.00 8.54 7.15.1.45.
the antibiotic sensitivity detection of micro-organisms with the unified system 1 study 8.19 0.00 8.19 7.15.1.46.
Botulism-bioprov 1 the examination 17.03 0.00 17.03 7.15.1.47.
plating on Clostridium botulinum (negative) 1 study 11.32 0.00 11.32 7.15.1.48.
plating on Clostridium botulinum (positive) 1 study 20.72 0.00 20.72 7.15.1.49.
distributed micro-organisms antibiotic sensitivity determination by disk method 1 study 6.83 0.00 6.83 7.15.1.50.
the culture of the different materials – MRSA Methicillin S. aureus (negative) study 7.15.1.51 5.45 0.00 5.45 1.
the culture of the different materials – MRSA Methicillin S. aureus (positive) 1 study 8.17 0.00 8.17 7.15.1.52.
in s. aureus Methicillin Mec Gene Discovery (MRSA) by polymerase chain reaction real time study 1st 44.63 0.00 44.63 7.15.1.53.
stools – Shigella, salmonella, with unified method (positive identification to serotype) 1 study 10.21 0.00 10.21 7.15.1.54.

plating of different materials on the Candida fungi of the genus with the unified system (positive, negative) 1 study 8.63 0.00 8.63 7.15.2.
7.15.2.1 serological analysis.
agglutination reaction in the case of bacterial infek information (such as whooping cough, typhoid fever, tularemia, brucellosis) 1 study 3.81 0.00 3.81 7.15.2.2.
Aspergillus Antigen with lateksagl in tinācij (LA) 1 study 7.44 0.00 7.44 7.15.2.3.
Candida Antigen with lateksagl in tinācij (LA) 1 study 7.44 0.00 7.44 7.15.2.4.
haemagglutination reaction bacterial infection in the year you (salmonellosis, šigel, yersiniosis, pseidotuberkuloz of Zea mays) 1 study 4.54 0.00 4.54 7.15.2.5.
Cryptococc of Antigen with lateksaglutinācij (LA) 1 study 10.43 0.00 10.43 7.15.2.6.
Clostridium difficile toxin A discovery 1 study 8.63 0.00 8.63 7.15.2.7.
Group a beta haemolytic Streptococcus in the quick test 1 study 2.97 0.00 2.97 7.15.2.8.
microscopic diagnosis of leprosy 1 study 1.84 0.00 1.84 7.16.
environmental studies 7.16.1 objects.
HAVE Ag (ELISA) – viral hepatitis A Antigen with imūnfer mentatīv reaction (sanitary examination) 1 study 8.96 0.00 8.96 7.16.2.
involved and the distribution of adenovīrus (sanitary examination) 1 study 33.09 0.00 33.09 7.16.3.
tick-borne encephalitis (TBE) virus Antigen (ELISA) imūnfermentatīv reaction to mite 1 study 10.97 0.00 10.97 7.16.4.
the washings of environmental objects (positive), 1 study 6.34 0.00 6.34 7.16.5 inoculum.
the washings of environmental objects (negative)-1 plating study 4.16 0.00 4.16 7.17.
laboratory studies of other medical institutions study the League 1-price-price 0.00 League 7.18.
morphological study of liver bioptāt-light microscopy study 1 19.55 0.00 19.55 8.
Image diagnostic 8.1.
ultrasonoskopisk investigation in 8.1.1.
abdominal sonogrāfij (not including the pelvic organs, with vascular measurement) 1 study 10.35 0.00 10.35 8.1.2.
one of the repeated sonogrāfij of organs (one study) study 1 5.90 0.00 5.90 8.1.3.
kidney, urinary tract, prostate sonogrāfij study 1 9.83 0.00 9.83 8.1.4.
a woman's pelvic organs examination 1 sonogrāfij 9.83 0.00 9.83 8.1.5.
mammary sonogrāfij 1 the examination 9.83 0.00 9.83 8.1.6.
Ultrasonic control made puncture 1 study 24.18 0.00 24.18 8.1.7.
thyroid, muscle, tendons, joints and other superficial structures ultrasound placed 1 study 9.32 0.00 9.32 8.1.8.
rectal and intravagināl sonogrāfij in study 1 8.28 0.00 8.28 8.2.
x-ray investigation 8.2.1.
the thoracic cavity organs 1 study screened 5.28 0.00 5.28 8.2.2.
the thoracic cavity organs review company 1 study 6.21 0.00 6.21 8.2.3.
the thoracic cavity organs company in two planes 1 study 9.32 0.00 9.32 8.2.4.
the thoracic cavity organs one extra company, including esophageal kontrastēšan 1 the examination 6.47 0.00 6.47 8.2.5.
other institutions of the radiograph evaluation one study 1 study 2.07 0.00 2.07 8.2.6.
abdominal examination 1 screened 4.71 0.00 4.71 8.2.7.
abdominal company 1 study 5.90 0.00 5.90 8.2.8.
Esophageal kontrastizmeklēšan (and Gramma screened) study 1 14.18 0.00 14.18 8.2.9.
esophageal, gastric and duodenal kontrastizmeklēšan 1 the examination of 22.44 0.00 22.44 8.2.10.
esophagus, stomach and duodenum to the rectum, small intestine kontrastizmeklēšan the investigation to study the ileocekāl area 1 24.89 0.00 24.89 8.2.11.
colon Arcade 1 study 20.37 0.00 20.37 8.2.12.
irigoskopij 1 the examination 37.90 0.00 37.90 8.2.13.
intravenous urogrāfij 1 the examination 21.97 0.00 21.97 8.2.14.
one tooth company 1 study 4.14 0.00 4.14 8.2.15.
mandibular x-ray images (biplane) 1 study 5.90 0.00 5.90 8.2.16.
skull x-ray images two planes 1 study 8.28 0.00 8.28 8.2.17.
skull x-ray each part 1 study 4.66 0.00 4.66 8.2.18.
Sinus one radiograph 1 study 5.18 0.00 5.18 8.2.19.
the chest bone or part of a single radiograph 1 study 6.21 0.00 6.21 8.2.20.
limb or part of a single radiograph 1 study 10.35 0.00 10.35 8.2.21.
the shoulder bar or pelvic radiograph of part 1 study 6.21 0.00 6.21 8.2.22.
pelvic bone radiograph 1 study report 6.47 0.00 6.47 8.2.23.
one part of the spine radiograph (biplane) 1 study 11.39 0.00 11.39 8.2.24.
a digital x-ray image recording on disc 1 study 1.55 0.00 1.55 8.2.25.
liver puncture Biopsy study 35.01 0.00 35.01 8.2.26 1.
larynx, throat, trachea, oesophagus, one of the top 1 study 5.54 0.00 5.54 8.2.27.
digital print on 24 x 30 cm film study 2.07 0.00 2.07 8.2.28 1.
digital print 35 x 43 cm to movie 1 study 2.07 0.00 2.07 9.
Functional diagnostics 9.1.
ezofagoskopij 1 the examination 10.97 0.00 10.97 9.2.
gastroskopij or duodenoskopij 1 the examination 30.00 0.00 30.00 9.3.
rektoskopij 1 the examination 7.66 0.00 7.66 9.4.
colon examination to lean angle 1 study 30.64 0.00 30.64 9.5.
total colon examination 1 study 50.00 0.00 50.00 9.6.
duodenāl probing study 9.47 0.00 9.47 9.7 1.
cleansing enema 1 study 4.45 0.00 4.45 9.8.
Pulse frequency and Arte in pressure of 1 Rial study 0.31 0.00 0.31 9.9.
electrocardiography with 12 leads (note) 1 study 2.02 0.00 2.02 9.10.
electrocardiography with 12 leads (description) 1 study 2.85 0.00 2.85 9.11.
electrocardiography with less than 12 Nova game (note) 1 study 0.83 0.00 0.83 9.12.
electrocardiography with less than 12 Nova game (description) 1 study 1.19 0.00 1.19 9.13.
During description (compared to at least five the ECG) 1 study 3.88 0.00 3.88 9.14.
electrocardiography (recorded with a portable machine on site) 1 study 4.66 0.00 4.66 9.15.
ehokardiogrāfij M and B mode real-time unit and haemodynamic indicators, dopplerogrāfij and spectral 1 study 26.20 0.00 26.20 9.16.
external breathing fundamentals (VC, and Tiffn with the index) discovery and analysis study 2.47 0.00 2.47 1 10.
Physical medicine 10.1.
1 study of galvanic 2.12 0.00 2.12 10.2.
medicine electrophoresis 1 study 2.69 0.00 2.69 10.3.
are modulated sinusoidal current (SMS) 1 study 2.12 0.00 2.12 10.4.
are modulated sinusoidal current (SMS) forēz 1 the examination 2.90 0.00 2.90 10.5.
cavities electrophoresis 1 study 2.59 0.00 2.59 10.6.
darsonvalizācij 1 the examination 1.85 0.00 1.85 10.7.
ultraīsviļņ therapy 1 study 1.48 0.00 1.48 10.8.
viļņterapij inches (monoplane) study 1 1.42 0.00 1.42 10.9.
inch viļņterapij (biplane) 1 study 1.66 0.00 1.66 10.10.
decimetre viļņterapij (monoplane) 1 study 1.45 0.00 1.45 10.11.
decimetre viļņterapij (biplane) 1 study 1.66 0.00 1.66 10.12.
ultrasound therapy 1 study 3.31 0.00 3.31 10.13.
1 3.83 0.00 3.83 10.14 fonoforēz study.
a changing magnetic field therapy 1 study 1.40 0.00 1.40 10.15.
ultraviolet irradiation of 1 study (de) agea 2.12 0.00 2.12.
solarium (face) 10 min * session * 1 0.93 0.20 1.13 10.17.
solarium (face) 20 min * session * 1 1.19 0.25 1.44 10.18.
solarium (face) 30 min * session * 1 1.40 0.29 1.69 favoured areas.
inhalation 1 session 2.59 0.00 2.59 10.20.
massage with massage apparatus 10 min 1 session 0.67 0.00 0.67 10.21.
massage with the massage machine 20 min session 1.40 0.00 1.40 10.22 1.
massage with massage apparatus 30 min session 1.76 0.00 1.76 10.23 1.
paraffin-ozokerite therapy procedure 4.14 0.00 4.14 10.24 1.
laser therapy-20 min session 2.25 0.00 2.25 1 10.25.
laser treatment 30 min session 1 2.90 0.00 2.90 10.26.
kriodestrukcij session 1 2.28 0.00 2.28 10.27.
laser therapy 5 min 1 session 0.70 0.00 0.70 10.28.
laser therapy session for 10 minutes 1 1.04 0.00 1.04 notes.
1. Value added tax does not apply, in accordance with the law "on value added tax" article 6, first paragraph, point 9.1.
2. The service provides patients the infection. "
The Prime Minister, the children, family and integration Affairs v. dombrovsky Health Minister i. Morris Editorial Note: the entry into force of the provisions by 13 May 2009.